Patients admitted with acute heart failure have a poor prognosis with a high risk of readmission and death after hospital discharge. [1] [2] [3] [4] This issue is focusing on this lifethreatening condition with world-wide contributions spanning from the far East to the far West.
Obesity is a significant risk factor for the development of heart failure, but on the other hand, is associated with a survival benefit in patients with established heart failure, known as the obesity paradox. An analysis from the ATTEND registry performed in Japan shows that low body weight is associated with a markedly increased cardiac mortality in acute heart failure patients. 5 The impact of body weight on mortality differed on heart failure etiology and the presence of hypertension, chronic obstructive pulmonary disease, and hyponatremia.
From a national registry in Portugal, we learn that patients hospitalized with an acute coronary syndrome and a mid-range ejection fraction (40-49%) represent an intermediate risk group in which beta-blocker treatment results in an in-hospital survival benefit. 6 Another study from the ATTEND registry assessed the impact of admission and discharge anemia status on the outcome of patients admitted with acute decompensated heart failure. 7 The effect of admission and discharge anemia status with outcomes differed between heart failure patients with a preserved or a reduced ejection fraction. In the patients with preserved ejection fraction, either development or persistence of anemia was associated with a worse outcome whereas, in patients with reduced ejection fraction, only persistent anemia was.
An international study comparing acute heart failure patients managed at tertiary centers in an Eastern (Singapore) versus a Western (USA) country showed that self-care barriers are highly prevalent among acute heart failure patients and differ substantially between East and West but without geographical differences in outcomes. 8 An analysis from the Japanese Heart Failure Syndrome with Preserved Ejection Fraction (JASPER) registry shows that hyponatremia at discharge is associated with adverse prognosis in hospitalized patients with heart failure with preserved ejection fraction. 9 A nationwide registry from Taiwan showed that in postinfarction patients surviving one year without recurrent myocardial infarction or stroke, the risk of subsequent cardiovascular events remains high for the next three years. 10 Significant predisposing risk factors were heart failure, hypertension, age, diabetes, stroke, chronic kidney disease, atrial fibrillation, and underutilization of guideline-based therapies.
In a study from Brazil on ST-elevation myocardial infarction patients admitted as Killip I, the increase of BNP during the first five days after admission was a stronger predictor than the GRACE score for the development within 12 months of symptomatic heart failure or a decreased ejection fraction and an increased incidence of sudden cardiac death or reinfarction at 30 days and after 12 months. 11 Based on the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial, 12 the current guidelines on the management of ST-elevation myocardial infarction recommend therapy with mineralocorticoid receptor antagonists in patients with a left ventricular ejection ≤40% and heart failure or diabetes, who are already receiving an angiotensin-converting enzyme inhibitor and a beta-blocker, provided there is no renal failure or hyperkalemia. 13 An analysis of a large contemporary cohort of acute coronary syndrome patients from two tertiary centers in Spain failed to corroborate this recommendation. 14 Although treatment with mineralocorticoid receptor antagonists resulted in a significantly lower incidence of major cardiovascular adverse events during long-term follow-up, there was no effect on heart failure development.
An analysis of a large national healthcare dataset from all Canadian provinces except Quebec showed a marked variation in intensive care utilization in patients hospitalized with acute heart failure; however, without any effect on in-hospital mortality. 15 In low utilization hospitals, the costs related to intensive care were significantly lower, indicating that development of standardized intensive care unit admission criteria limiting the use of higher-cost intensive care beds to higher acuity patients with heart failure could substantially reduce costs to the healthcare system.
Instead of a specific disease, acute heart failure is a clinical syndrome defined by changes in symptoms and signs that can be triggered by a wide variety of precipitant factors. An analysis of the data from an extensive Spanish multicentre registry on the epidemiology of acute heart failure in emergency departments (EAHFE) assessed the prevalence and prognostic value of the most common triggering factors in acute heart failure. 16 Infection and atrial fibrillation were the most common precipitants. Among all precipitant factors, an acute coronary syndrome was associated with a markedly increased 30-day mortality, whereas infection and atrial fibrillation were associated with better outcomes. These findings suggest that patients hospitalized with acute heart failure may present different levels of vulnerability during the first 30 days after admission depending on the presence of distinctive precipitant factors that may need different more specific therapeutic strategies and regimens.
